News
04-14-2013, 11:40 PM
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.
More... (http://www.news-medical.net/news/20130415/Navidea-presents-Phase-3-Lymphoseek-study-results-at-international-symposium-in-Athens.aspx)
More... (http://www.news-medical.net/news/20130415/Navidea-presents-Phase-3-Lymphoseek-study-results-at-international-symposium-in-Athens.aspx)